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Medication-related osteonecrosis

Patients with a hidden risk of MRONJ
Sir, in secondary care we see many cases of medication-related osteonecrosis of the jaw (MRONJ). The referring dentists are often blind-sided by the diagnosis, as their patients may not have disclosed the use any of MRONJ-related medicines. I' d like to highlight to readers a group of patients who should raise suspicion of being at risk of MRONJ.
Bisphosphonates (BPs) are the mainstay pharmacological treatment for patients with osteoporosis. Once absorbed, their half-life is over ten years. 1 They are also used in many other conditions, including metabolic bone disorders and bone cancer. Dentists should have a high index of suspicion in patients with a history of the above conditions, or if they are displaying signs and symptoms of osteoporosis (Box 1). 2 Discussing their past drug history is important. It is also wise to enquire if they have ever attended hospitals for injectable medications. Intra-venous (IV) BPs place patients at a particularly high risk of MRONJ, and patients often forget about them. 3 Approximately a fifth of patients on oral BPs will be switched to a different medication due to intolerances. Commonly, these are in the form of gastric irritation or muscoskeletal pain. 4 Oral agents they can be switched to include vitamin D, calcium, HRT (eg Raloxifene) and strontium ranelate.
Alternatively, they may be switched to parenteral medicines such as IV BPs, parathyroid hormone (teriparatide) or denosumab. 5 A patient presenting with a combination of any of these medications should be treated with a high index of suspicion for historic BP use. In such circumstances, we suggest calling the patient's GP practice. With the patient's permission, they can provide a more reliable drug history.
In addition to BPs, other MRONJ-related medicines include RANKL inhibitors (denosumab) and anti-angiogenic drugs (bevacizumab, sunitinib, flibercept).
